Ironwood Pharmaceuticals ...

1.42
-0.11 (-7.19%)
At close: Mar 21, 2025, 3:59 PM
1.40
-1.20%
After-hours: Mar 21, 2025, 06:52 PM EDT
-7.19%
Bid 1.38
Market Cap 227.24M
Revenue (ttm) 352.12M
Net Income (ttm) 73.19M
EPS (ttm) 0.01
PE Ratio (ttm) 142
Forward PE 17.88
Analyst Buy
Ask 1.42
Volume 3,179,062
Avg. Volume (20D) 3,038,689
Open 1.52
Previous Close 1.53
Day's Range 1.37 - 1.55
52-Week Range 1.34 - 9.10
Beta 0.37

About IRWD

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European...

Sector Healthcare
IPO Date Feb 3, 2010
Employees 267
Stock Exchange NASDAQ
Ticker Symbol IRWD
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for IRWD stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 604.23% from the latest price.

Stock Forecasts

Next Earnings Release

Ironwood Pharmaceuticals Inc. is scheduled to release its earnings on May 8, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-38.17%
Ironwood Pharmaceuticals shares are trading lower.... Unlock content with Pro Subscription
1 month ago
-2.11%
Ironwood Pharmaceuticals shares are trading lower. The company board announced approval for a 50% reduction in the workforce.